Acquired resistance to: T-DM1, Taxol
BT-474 cells
Human BT-474 cells were isolated from the mammary gland of a patient with breast ductal carcinoma.
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing BT-474 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the BT-474 cells as xenograft Mean ± SEM (n=6; take rate 100%)
Antineo can also implant this model orthotopically.
Standard-Of-Care Drug Responses
T-DM1 3 mg/kg → Response
Figure 2: (View PDF)
Effect of T-DM1 treatment on BT-474 tumour growth
Mean ± SEM (n=10 per group; take rate 100%)
A BT474 resistant to T-DM1 model, developed in vivo without genetic modifications, are available at Antineo (model ID BT474 TDM1R).